Nothing Special   »   [go: up one dir, main page]

MX2019002115A - Terapias de combinacion para el tratamiento de carcinoma hepatocelular. - Google Patents

Terapias de combinacion para el tratamiento de carcinoma hepatocelular.

Info

Publication number
MX2019002115A
MX2019002115A MX2019002115A MX2019002115A MX2019002115A MX 2019002115 A MX2019002115 A MX 2019002115A MX 2019002115 A MX2019002115 A MX 2019002115A MX 2019002115 A MX2019002115 A MX 2019002115A MX 2019002115 A MX2019002115 A MX 2019002115A
Authority
MX
Mexico
Prior art keywords
hepatocellular carcinoma
treatment
combination therapies
inhibitor
combination
Prior art date
Application number
MX2019002115A
Other languages
English (en)
Inventor
Selvaraj Anand
Smith Peter
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2019002115A publication Critical patent/MX2019002115A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporciona en la presente una terapia de combinación útil para el tratamiento de carcinoma hepatocelular y/o colangiocarcinoma intrahepático. La combinación comprende un inhibidor de FGFR4 y un inhibidor de CDK 4/6.
MX2019002115A 2016-08-23 2017-08-23 Terapias de combinacion para el tratamiento de carcinoma hepatocelular. MX2019002115A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662378455P 2016-08-23 2016-08-23
PCT/US2017/048183 WO2018039324A1 (en) 2016-08-23 2017-08-23 Combination therapies for the treatment of hepatocellular carcinoma

Publications (1)

Publication Number Publication Date
MX2019002115A true MX2019002115A (es) 2019-07-08

Family

ID=59772765

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002115A MX2019002115A (es) 2016-08-23 2017-08-23 Terapias de combinacion para el tratamiento de carcinoma hepatocelular.

Country Status (14)

Country Link
US (1) US20190175598A1 (es)
EP (1) EP3503923B1 (es)
JP (1) JP7190425B2 (es)
KR (1) KR102466192B1 (es)
CN (1) CN109803684B (es)
AU (1) AU2017315357B2 (es)
BR (1) BR112019003722A2 (es)
CA (1) CA3034875C (es)
ES (1) ES2966469T3 (es)
IL (1) IL264950B2 (es)
MX (1) MX2019002115A (es)
RU (1) RU2769251C2 (es)
SG (1) SG11201901472TA (es)
WO (1) WO2018039324A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202005937QA (en) 2018-01-08 2020-07-29 G1 Therapeutics Inc G1t38 superior dosage regimes
ES2968899T3 (es) * 2018-05-14 2024-05-14 Pfizer Formulación de la solución oral
TW202128173A (zh) * 2019-10-09 2021-08-01 美商G1治療公司 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療
WO2021230886A1 (en) * 2020-05-15 2021-11-18 Eisai R&D Management Co., Ltd. A method for treating cancer with an oral dosage form of an fgfr4 inhibitor

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399633B1 (en) 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
DE19959546A1 (de) 1999-12-09 2001-06-21 Rhone Poulenc Rorer Gmbh Pharmazeutische Zubereitung zur Behandlung von Tumorerkrankungen
ATE284400T1 (de) 2000-01-18 2004-12-15 Aventis Pharma Inc Ethanolsolvat von (-)-cis-2-(2-chlorphenyl)-5,7- dihydroxy-8- (4r-(3s-hydroxy-1- methyl)piperidinyl)-4h-1-benzopyran-4-on
WO2001053293A1 (en) 2000-01-18 2001-07-26 Aventis Pharmaceuticals Inc. Pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one
WO2002022133A1 (en) 2000-09-12 2002-03-21 Virginia Commonwealth University Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
EA007395B3 (ru) 2002-01-22 2018-02-28 Уорнер-Ламберт Компани Ллс 2-(ПИРИДИН-2-ИЛАМИНО)ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНЫ
PL2256106T3 (pl) 2003-07-22 2015-08-31 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
CA2594474C (en) 2005-01-21 2016-03-29 Astex Therapeutics Limited Pharmaceutical compounds
ES2552338T3 (es) 2005-01-21 2015-11-27 Astex Therapeutics Limited Compuestos farmacéuticos
BRPI0606319A2 (pt) 2005-01-21 2009-06-16 Astex Therapeutics Ltd compostos farmacêuticos
JP2008255008A (ja) 2005-07-19 2008-10-23 Tokyo Medical & Dental Univ 滑膜細胞増殖抑制剤
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
WO2008001101A2 (en) 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations
US20090263398A1 (en) 2006-07-14 2009-10-22 Astex Therapeutics Limited Pharmaceutical combinations
JP2009543770A (ja) 2006-07-14 2009-12-10 アステックス・セラピューティクス・リミテッド Ｃｄｋ及びｇｓｋの阻害のためのピラゾール誘導体の組合せ剤
EP2046327A1 (en) 2006-07-21 2009-04-15 Astex Therapeutics Limited Medical use of cyclin dependent kinases inhibitors
EP1918376A1 (en) * 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
US7902147B2 (en) 2007-11-05 2011-03-08 Duke University Chronic lymphocytic leukemia prognosis and treatment
MX2010012699A (es) * 2008-05-23 2010-12-07 Novartis Ag Derivados de quinolinas y quinoxalinas como inhibidores de cinasa de proteina tirosina.
PL2331547T3 (pl) 2008-08-22 2015-01-30 Novartis Ag Związki pirolopirymidynowe jako inhibitory CDK
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
CN102869358B (zh) 2010-04-13 2016-03-23 诺华股份有限公司 用于治疗癌症的包含细胞周期蛋白依赖性激酶4或细胞周期蛋白依赖性激酶6(CDK4/6)抑制剂和mTOR抑制剂的组合
HUE030714T2 (en) 2010-10-25 2017-05-29 G1 Therapeutics Inc CDK inhibitors
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
US8623885B2 (en) 2011-03-23 2014-01-07 Amgen Inc. Fused tricyclic dual inhibitors of CDK 4/6 and FLT3
EP2726076B1 (en) * 2011-07-01 2016-10-12 Novartis AG Combination therapy
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
WO2014097125A1 (en) 2012-12-20 2014-06-26 Novartis Ag Pharmaceutical combination comprising binimetinib
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
EP2968290B1 (en) 2013-03-15 2019-09-25 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
ES2900829T3 (es) * 2013-08-14 2022-03-18 Novartis Ag Terapia combinada para el tratamiento del cáncer
PL3057943T3 (pl) 2013-10-18 2018-09-28 Eisai R&D Management Co., Ltd. Inhibitory FGFR4 pirymidyny
WO2016025650A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
CN104529904B (zh) 2015-01-09 2016-08-31 苏州明锐医药科技有限公司 玻玛西尼的制备方法
US20160220569A1 (en) 2015-02-03 2016-08-04 G1 Therapeutics, Inc. CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy
KR102548229B1 (ko) * 2015-04-14 2023-06-27 에자이 알앤드디 매니지먼트 가부시키가이샤 결정질 fgfr4 억제제 화합물 및 그의 용도

Also Published As

Publication number Publication date
JP2019528302A (ja) 2019-10-10
RU2769251C2 (ru) 2022-03-29
IL264950B1 (en) 2023-09-01
US20190175598A1 (en) 2019-06-13
SG11201901472TA (en) 2019-03-28
EP3503923A1 (en) 2019-07-03
ES2966469T3 (es) 2024-04-22
RU2019108259A (ru) 2020-09-25
KR20190040996A (ko) 2019-04-19
EP3503923B1 (en) 2023-10-04
IL264950A (en) 2019-05-30
AU2017315357A1 (en) 2019-02-28
WO2018039324A1 (en) 2018-03-01
CN109803684A (zh) 2019-05-24
KR102466192B1 (ko) 2022-11-14
JP7190425B2 (ja) 2022-12-15
IL264950B2 (en) 2024-01-01
CA3034875A1 (en) 2018-03-01
AU2017315357B2 (en) 2022-12-01
CA3034875C (en) 2024-05-28
BR112019003722A2 (pt) 2019-05-28
CN109803684B (zh) 2022-08-23
RU2019108259A3 (es) 2020-11-24

Similar Documents

Publication Publication Date Title
IL272948A (en) ENPP1 inhibitors and their use for cancer treatment
MX2020003939A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos.
MX2022008868A (es) Tratamiento del cancer con tg02.
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
EP4302835A3 (en) Methods of treating ovarian cancer
MX2019002115A (es) Terapias de combinacion para el tratamiento de carcinoma hepatocelular.
CO2017013065A2 (es) Moduladores de diaciglicerol aciltransferasa 2 (dgat2)
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
MX2018006152A (es) Metodos para el tratamiento de cancer utilizando inhibidores b-raf e inhibidores de punto de control inmunologico.
MX2020004724A (es) Composiciones de inh-c1 y métodos para la prevención y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
MX2018010709A (es) Terapia del cancer con un virus oncolitico combinado con un inhibidor de punto de control.
PH12019501373A1 (en) Methods of treating cochlears synaptopathy
MX2018011875A (es) Reprogramacion cardiaca directa mejorada.
MX2019010981A (es) Terapias de combinacion para el tratamiento de cancer de mama.
MY201580A (en) Use of ezh2 inhibitor combined with btk inhibitor in preparing drug for treating tumor
EA201890728A2 (ru) Лечение ингибиторами ntcp атеросклероза, первичного билиарного цирроза и заболевания, связанного с nrlp3-инфламмасомами
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
GB201721793D0 (en) Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza
MX2021006312A (es) Inhibidores de magl para usarse para tratar enfermedades.
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
EP3426256A4 (en) METHOD OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR EVENTS AND DISEASES ASSOCIATED WITH SGLT-2 INHIBITOR
WO2016046414A3 (en) Cdc25a inhibitor for the treatment of drug resistant cancer or for the prevention of tumor relapse
MX2020007375A (es) Terapias de combinacion para el tratamiento de carcinoma hepatocelular.
MX2019002524A (es) Caja para dispositivo de tratamiento dental.